Dimitri de Failly

Moleac Pte Ltd. develops and distributes biopharmaceutical products. It operates as a bio-pharmaceutical company that develops new medicines for the unmet needs of patients suffering from neurological, cardio-vascular and aging conditions. The firm's flagship product NeuroAiD, helps patients recover faster and better from stroke disabilities. The company was founded by David Picard and Marc Vasseur in 2003 and is headquartered in Singapore.

Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium.

FORMAC Pharmaceuticals NV engages in drug delivery and development services. The firm applies its silica based drug delivery platforms for improving in vivo performance of poorly soluble compounds. The company was founded by Johan A. Martens, Paul Joseph Rutgeerts, Guy Van den Mooter and Jan Baptist Van Humbeeck in 2007 and is headquartered in Heverlee, Belgium.

Hunza Ventures II SCA SICAR focuses on making investments in the biotech, pharmaceutical, medtech and high-tech industries.

Part of Somadin, Herpain Urbis NV is a Belgian real estate development company. The company is based in Brussels, Belgium. Herpain Urbis was founded by Laurent J. Degryse. The CEO is Yvan Neirinckx.

Exact Imaging, Inc. provides high resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Its ExactVu micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and being an extension of the current urological workflow. The company was founded by Sam Ifergan and Randy AuCoin in 2013 and is headquartered in Markham, Canada.

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.

FEops NV develops novel simulation technology. It provides cardiovascular device and procedure simulation advice to medical device companies, as well as to medical specialists and physicians. The firm develops disruptive technology: a cloud-based simulation platform designed to assist clinicians in assessing the effect of device-and-host interaction, with the ultimate goal of predicting and preventing complications of transcatheter-based structural heart interventions. The company was founded by Benedict Verhegghe, Matthieu De Beule and Peter Mortier in 2009 and is headquartered in Ghent, Belgium.

Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium.

Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium.

eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium.

American Discovery Capital LLC (American Discovery) is a private equity firm founded in 2016 by John P. Joliet. The firm is headquartered in Los Angeles. California.

EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium.

Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation.

Finlight.Com Ltd. provides asset management software. The company was founded by Jean-Bernard Tanqueray and Yves Coignard and is headquartered in London, the United Kingdom.

Herpain Urbis Retail Holding SA is an investment holding Belgian company. The private company is based in Uccle, Belgium. The company was founded in 2015. Yvan Neirinckx has been the CEO of the company since 2015.

The Museum of Contemporary Art, Los Angeles operates a gallery for contemporary art. It services include collection, presentation, and interpretation of art and to preserving for future generations. The company was founded in 1979 and headquartered in Los Angeles, CA.

Sony Depthsensing Solutions SA/NV provides gesture-based platforms for the consumer electronics and professional markets. Its products include depthsense sensors, depthsense cameras and depthsense middleware. The company was founded by Eric Krzelso, Michel Tombroff and Daniel van Nieuwenhove in July 2007 and is headquartered in Brussels, Belgium.

Sony Depthsensing Solutions Holding SA provides image sensor technology. It offers a complete family of 3 dimensional imaging and gesture recognition solutions, including patented 3D complementary metal-oxide semiconductor (CMOS) time-of-flight sensors and cameras, multi-platform and multi-camera 3D gesture recognition middleware, and tools as well as games and applications. The company was founded by Eric Krzeslo and Daniël Van Nieuwenhove in July 2007 and is headquartered in Brussels, Belgium.

Pacific Oak Strategic Opportunity REIT II, Inc. operates as a real estate investment trust. It intends to acquire distressed debt, to originate and acquire mortgage, mezzanine, bridge and other real estate-related loans, to invest in various types of opportunistic real estate and to invest in real estate-related debt securities such as residential and commercial mortgage-backed securities and collateralized debt obligations. The company was founded on February 6, 2013 and is headquartered in Los Angeles, CA.